CohBar, Morphogenesis link up in reverse merger of two cancer biotechs
23 May 2023
VaccineImmunotherapymRNAClinical Study
The cancer-focused Bay Area biotech CohBar is entering into a reverse merger with the privately-held biotech Morphogenesis.
On Tuesday, CohBar and Morphogenesis
announced
the all-stock transaction. The newly combined company will operate under the name TuHURA Biosciences and trade on the Nasdaq. The deal is expected to close in the third quarter.
TuHURA, which will be based in Tampa, FL, will focus on advancing three products based on Morphogenesis technologies designed to treat cancer. Two are personalized cancer vaccines, which aim to activate an innate immune response against patient-specific tumor antigens. The company is preparing for a Phase II/III trial in 2024 of its lead cancer vaccine, designed to act as an adjunct to Merck’s Keytruda in advanced Merkel cell carcinoma. It is also looking to advance its other mRNA-based vaccine to treat aggressive diffuse large B-cell lymphoma. Morphogenesis’ other product, called Tumor Microenvironment Modulator, is designed to address resistance of immunotherapies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.